Longeveron (LGVN) Change in Receivables (2020 - 2026)
Longeveron (LGVN) posted quarterly Change in Receivables of -$36000.0 for Q1 2026, up 34.55% year-over-year from -$26756.8 in Q1 2025, and down 169.23% quarter-over-quarter from $52000.0 in Q4 2025.
Longeveron (LGVN) Change in Receivables (2020 - 2026) Analysis & Trends
Longeveron's Change in Receivables history runs 7 years deep, the most recent figure standing at -$36000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 34.55% year-over-year to -$36000.0; the TTM figure through Mar 2026 stood at $39000.0 (up 126.17% YoY), while the FY2025 annual figure was $20000.0, up 174.07% from the prior year.
- Change in Receivables for Q1 2026 stood at -$36000.0, down from $52000.0 in the prior quarter.
- The five-year high for Change in Receivables was $162000.0 in Q3 2024, with the low at -$296000.0 in Q4 2024.
- The 5-year median for Change in Receivables is $40000.0 (2022), against an average of $933.33.
- Peak annual rise in Change in Receivables reached 154.92% in 2024, while the deepest fall reached 2073.33% in 2024.
- Longeveron's Change in Receivables stood at $42000.0 in 2022, then sank by 64.29% to $15000.0 in 2023, then slumped by 2073.33% to -$296000.0 in 2024, then surged by 117.57% to $52000.0 in 2025, then tumbled by 169.23% to -$36000.0 in 2026.
- Business Quant data shows LGVN's Change in Receivables at -$36000.0 in Q1 2026, $52000.0 in Q4 2025, and $21000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Jun 30, 2026 | -3,000.00 |
| Mar 31, 2026 | -36,000.00 |
| Mar 31, 2026 | -36,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -55,000.00 |
| Mar 31, 2025 | -55,000.00 |
| Dec 31, 2024 | -296,000.00 |
| Dec 31, 2024 | -296,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |